Metaiodobenzylguanidine scintigraphy in pulmonary and cardiac disease

Kroonenburgh, Marinus van; Mostard, Rémy L M; Vöö, Stefan

doi:10.1097/mcp.0b013e32833b1e1f

Cited by 7 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although extracellular 123 I-MIBG increases because of decreased extraction of circulating 123 I-MIBG to damaged AECs and sympathetic neurons, decreased perfusion disrupts back-diffusion of this component to systemic circulation (15,17,21). Lack of integrity or dysfunction of AECs in PE patients also decreases the 123 I-MIBG washout rate, as various other lung disorders with injury of AECs persistently show a decreased 123 I-MIBG washout rate (16,18,(20)(21)(22)(23)34).…”

Section: Rgbmentioning

confidence: 99%

“…123 I-metaiodobenzylguanidine ( 123 I-MIBG) shares the same uptake as norepinephrine in AECs (12)(13)(14)(15). 123 I-MIBG scintigraphic studies have been used to detect and assess the functional injury or integrity of AECs in various lung diseases, including PE (16)(17)(18)(19)(20)(21)(22)(23). SPECT provides better assessment of lung 123 I-MIBG uptake than planar scanning and allows cross-sectional comparisons with lung morphologic CT scans and perfusion SPECT scans.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Impaired Lung ¹²³I-MIBG Uptake on SPECT in Pulmonary Emphysema

Suga¹,

Okada

Kunihiro

et al. 2011

J Nucl Med

View full text Add to dashboard Cite

The aim of this study was to evaluate impaired lung uptake of 123 I-metaiodobenzylguanidine ( 123 I-MIBG) on SPECT, compared with perfusion SPECT and morphologic CT, in patients with pulmonary emphysema (PE). Methods: 123 I-MIBG SPECT was performed at 15 min and 4 h after intravenous injection of 123 I-MIBG in 36 PE patients with a history of smoking and variable-extent low-attenuation areas on CT, indicative of emphysematous changes, and in 16 controls with no history of smoking and no noticeable low-attenuation areas. The distribution of 123 I-MIBG was compared with that of low-attenuation areas on CT and perfusion on SPECT at the base of the 180 lung lobes of the PE patients. Total-lung 123 I-MIBG kinetics were calculated, including early and delayed lung-to-mediastinum uptake ratios and washout rate. Results: The controls showed a fairly uniform lung 123 I-MIBG distribution nearly consistent with perfusion. PE patients had heterogeneous 123 I-MIBG defects showing frequent discordance with low-attenuation areas or perfusion distribution; 123 I-MIBG defects were more extensive than low-attenuation areas in 76 lobes (42.2%) of 31 patients (86%) and more extensive than perfusion defects in 44 lobes (24.4%) of 22 patients (61%). 123 I-MIBG defects were seen regardless of the absence of noticeable low-attenuation areas and perfusion defects in 19 lobes (10.5%) of 16 patients (44%). All total-lung 123 I-MIBG kinetic parameters in PE patients were significantly lower than the control values (P , 0.0001), with significant correlation with alveolar-arterial oxygen tension gradient but without correlation with the extent of perfusion defects or low-attenuation areas. Conclusion: 123 I-MIBG SPECT allows evaluation of lung pathophysiology in PE independently of perfusion SPECT or morphologic CT, and impairment of lung 123 I-MIBG uptake may be more extensive than perfusion or morphologic abnormalities in PE.

show abstract

Section: Rgbmentioning

confidence: 99%

mentioning

confidence: 99%

Impaired Lung ¹²³I-MIBG Uptake on SPECT in Pulmonary Emphysema

Suga¹,

Okada

Kunihiro

et al. 2011

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…The lungs extract circulating NE by a specific transporter located in the vascular endothelium and this biologic function has been exploited for molecular imaging of the pulmonary vasculature. This energy-dependent process was imaged using 123 I-metaiodobenzylguanidine (MIBG) scintigraphy, studying the lung uptake and wash-out of the radioimaging agent [ 69 ]. Studies have shown diminished lung extraction of 123 I-MIBG in patients with chronic obstructive pulmonary disease, pulmonary fibrosis, vasculitis, and after radiotherapy and high altitude hypoxia [ 70 – 74 ].…”

Section: Molecular Imaging Of the Pulmonary Vasculaturementioning

confidence: 99%

“…Despite its potential, this agent is not currently used for diagnosis of lung vascular disorders. The lung imaging technique with 123 I-MIBG has never been standardized and the biology of the tracer remains uncertain as lung neuronal uptake, in addition to endothelial uptake, likely contributes to the kinetics of this tracer [ 69 ].…”

Section: Molecular Imaging Of the Pulmonary Vasculaturementioning

confidence: 99%

Molecular imaging of the pulmonary circulation in health and disease

Dupuis

Harel

Nguyen

2014

Clin Transl Imaging

View full text Add to dashboard Cite

The pulmonary circulation, at the unique crossroads between the left and the right heart, is submitted to large physiologic hemodynamic variations and possesses numerous important metabolic functions mediated through its vast endothelial surface. There are many pathologic conditions that can directly or indirectly affect the pulmonary vasculature and modify its physiology and functions. Pulmonary hypertension, the end result of many of these affections, is unfortunately diagnosed too late in the disease process, meaning that there is a crying need for earlier diagnosis and surrogate markers of disease progression and regression. By targeting endothelial, medial and adventitial targets of the pulmonary vasculature, novel molecular imaging agents could provide early detection of physiologic and biologic perturbation in the pulmonary circulation. This review provides the rationale for the development of molecular imaging agents for the diagnosis and follow-up of disorders of the pulmonary circulation and discusses promising targets for SPECT and positron emission tomographic imaging.

show abstract